c-erb B-2 Expression Is Associated with Tumor Location and Venous Invasion and Influences Survival of Patients with Gastric Carcinoma

Abstract

The HER-2/neu gene or c-erb B-2, localized on chromosome 17q, belongs to a family of tyrosine kinase receptors and shares extensive homology with the epidermal growth factor receptor. c-erb B-2 gene amplification and protein overexpression have been reported in several human cancers. The prognostic value of this genetic alteration in gastric carcinoma is far from being established. In the present study, formalin-fixed, paraffin-embedded gastric carcinoma tissues from 157 patients were evaluated for c-erb B-2 overexpression, by immunohistochemistry using a polyclonal antibody. c-erb B-2 expression was evaluated according to clinical and pathological parameters, and to the survival of the patients. Our results show that: (1). c-erb B-2 was overexpressed in 15.3% of gastric carcinoma cases; (2). c-erb B-2 overexpression was significantly more frequent in cardia (23.8%) and fundus/body (25.0%) carcinomas than in antrum (7.2%) carcinomas; (3). c-erb B-2 overexpression was significantly associated with venous invasion; (4). c-erb B-2 is a prognostic factor for gastric carcinoma.

Correlation of c-erbB-2, EGF and EGFR expression with postoperative survival of patients with advanced carcinoma of the stomach.

“…There was also no association between the expression of c-erbB-2, EGF in gastric tumor and depth of invasion or histological differentiation. Moreover, no correlation was observed between positive staining for EGF and EGFR in the main mass of tumor and Bormann's classification, which was in agreement with other authors [25,26]. Tsigris et al [28] found no correlation between c-erbB-2 expression in gastric carcinoma and histological subtype, differentiation grade, tumor location, TNM stage, gastric wall invasion depth and pres- Table 2.…”

Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review

“…Wang et al, 10 Marx et al, 15 Song et al, 30 Garcia et al, 31 Ghaderi et al, 36 Oshima et al, 38 Allgayer et al 39 Wang et al, 10 Marx et al, 15 Zhang et al, 18 Potrc et al, 23 Garcia et al, 31 Ghaderi et al, 36 Wang et al, 37 Allgayer et al 39 Zhang et al, 18 Yu et al, 19 Potrc et al, 23 Park et al, 24 Lee et al, 32 Pinto-de-Sousa et al, 34 Ghaderi et al, 36 Allgayer et al 39 [11 Studies (3 studies between 1990 and 1999 not displayed)]…”

“…Early Grabsch et al, 11 Marx et al, 15 Yu et al, 19 Hayashi et al, 22 Potrc et al, 23 Song et al, 30 Pinto-de-Sousa et al, 34 Ghaderi et al 36 [15 Studies (7 studies between 1990 and 1999 not displayed)]…”

“…Not specified Wang et al, 10 Im et al 27 [2 Studies] Marx et al, 15 Yu et al, 19 Hayashi et al, 22 Satiroglu-Tufan et al, 25 Ghaderi et al, 36 Allgayer et al 39 15 Barros-Silva et al, 16 Hayashi et al, 22 Park et al, 24 Tanner et al, 26 Song et al, 30 Garcia et al, 31 Lee et al, 32 Pintode-Sousa et al, 34 Oshima et al 38 [12 Studies (2 studies between 1990 and 1999 not displayed)]…”

“…III/IV Wang et al, 10 Zhang et al, 18 Im et al, 27 Ghaderi et al, 36 Allgayer et al 39 [5 Studies] Presence of microvascular invasion Wang et al, 10 Pinto-de-Sousa et al, 34 Allgayer et al 39 [3 Studies] Grabsch et al, 11 Barros-Silva et al, 16 Park et al, 24 Garcia et al 31 [8 Studies (4 studies between 1990 and 1999 not displayed)]…”